# Tessera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tessera-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.tesseratx.com/
- Total disclosed funding: $632M
- Latest round: Series C (Apr 19, 2022)
- Investors on record: 13

## About

Based in the US, Tessera Therapeutics, Inc. specializes in Gene Writing™, leveraging innovative genome engineering technology to address genetic disorders at their root causes.Tessera Therapeutics, Inc. is focused on genome engineering, integrating therapeutic messages into the human genome. Founded in 2018 in Cambridge, US, by Jacob Rubens, Noubar Afeyan, and Robert Citorik, the company has secured funding through 3 significant deals. The latest, a Series C round, raised USD 400.00 mn on 18 December 2024, from investors including ARTIS Ventures and the Bill & Melinda Gates Foundation. The company currently has a valuation of USD 1,385.89 mn, led by CEO Michael Severino.Tessera Therapeutics specializes in Gene Writing™, a transformative genome engineering technology designed to address the underlying causes of genetic diseases by directly integrating therapeutic messages into the genome. The company develops non-viral delivery systems for permanent, tissue-targeted genomic modifications, primarily targeting genetic disorders such as sickle cell disease and T-cell-related conditions. Their services cater to healthcare providers, research institutions, and biotechnology firms across North America and Europe, striving to advance genetic medicine and meet critical medical needs.Tessera Therapeutics generates revenue through strategic partnerships and collaborations with healthcare organizations, research institutions, and pharmaceutical companies focused on genetic therapies. Their financial model is built on collaborative research agreements and milestone-based funding, with revenue streams supported by ongoing projects, including in vivo genetic treatments for sickle cell disease and other therapeutic areas as they expand their innovative portfolio.In December 2024, Tessera Therapeutics raised USD 400.00 mn in a Series C round to enhance research and development in their sickle cell disease program. The company is focused on launching new genetic therapies and plans to expand into new markets in North America and Europe by 2025. The funds will be applied to accelerate the development and commercialization of their Gene Writing technologies, targeting significant health issues through innovative solutions.

## Funding rounds

- Series C, Apr 19, 2022, $400M — Flagship Pioneering, T Rowe Price, Alaska Permanent Fund Corporation, Abu Dhabi Investment Authority, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, March Capital, SB Investment Advisers, Longevity Vision Holding, Salt Ventures, Hanwha Impact Partners
- Series B, Jan 12, 2021, $232M — Alaska Permanent Fund Corporation, Altitude Life Science Ventures, Qatar Investment Authority, SB Investment Advisers

## Investors

- Alaska Permanent Fund Corporation — Series B, Series C
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series B, Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B, Series C
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Abu Dhabi Investment Authority — Series C
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- March Capital (https://capitalatlas.ai/funds/march-capital) — Series C
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series C
- Salt Ventures — Series C
- Hanwha Impact Partners (https://capitalatlas.ai/funds/hanwha-impact-partners) — Series C